A comprehensive clinical assessment plus a brain MRI needs to take place, ideally complemented by further imaging techniques (e.g. FDG-PET, amyloid-PET or tau-PET) and/or laboratory tests (e.g. CSF biomarkers for AD or neurofilament light chain) to increase diagnostic certainty [7, 33]. The gene discussed is MAPT; the disease is Alzheimer disease.